Free Trial

Cibus Q2 2024 Earnings Report

Cibus logo
$1.98 -0.11 (-5.26%)
As of 04:00 PM Eastern

Cibus EPS Results

Actual EPS
-$1.14
Consensus EPS
-$0.81
Beat/Miss
Missed by -$0.33
One Year Ago EPS
-$3.05

Cibus Revenue Results

Actual Revenue
$0.84 million
Expected Revenue
$0.44 million
Beat/Miss
Beat by +$400.00 thousand
YoY Revenue Growth
N/A

Cibus Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Remove Ads

Cibus Earnings Headlines

Cibus negotiations with EU moving forward is significant, says Canaccord
HC Wainwright Predicts Cibus' Q1 Earnings (NASDAQ:CBUS)
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Cibus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cibus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cibus and other key companies, straight to your email.

About Cibus

Cibus (NASDAQ:CBUS), a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

View Cibus Profile

More Earnings Resources from MarketBeat